Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Wang, Guan ^a,b   Edwards, Holly ^a   Caldwell, J Timothy ^a   Buck, Steven A ^c   Qing, William Y ^a   Taub, Jeffrey W ^a,c   Ge, Yubin ^a,b   Wang, Zhihong ^a,c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JILIN UNIVERSITY   (China)

^c CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 1; CISPLATIN; CYCLIN DEPENDENT KINASE 1; DOXORUBICIN; ETOPOSIDE; PANOBINOSTAT; RABUSERTIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INCUBATION TIME; NEUROBLASTOMA; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; ETOPOSIDE; G2 PHASE CELL CYCLE CHECKPOINTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; NEUROBLASTOMA; PHENYLUREA COMPOUNDS; PROTEIN KINASES; PYRAZINES;

EID: 84884778458     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076662     Document Type: Article

References (33)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL, (2007) Neuroblastoma. Lancet 369: 2106-2120.
2. Modak S, Cheung NK, (2010) Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treat Rev 36: 307-317.
3. Hara J, (2012) Development of treatment strategies for advanced neuroblastoma. Int J Clin Oncol 17: 196-203.
4. Russo C, Cohn SL, Petruzzi MJ, de Alarcon PA, (1997) Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 28: 284-288.
5. Halperin EC, Cox EB, (1986) Radiation therapy in the management of neuroblastoma: the Duke University Medical Center experience 1967-1984. Int J Radiat Oncol Biol Phys 12: 1829-1837.
6. Bolderson E, Richard DJ, Zhou BB, Khanna KK, (2009) Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res 15: 6314-6320.
7. Lapenna S, Giordano A, (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8: 547-566.
8. Dai Y, Grant S, (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 16: 376-383.
9. Garrett MD, Collins I, (2011) Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol Sci 32: 308-316.
10. Marks PA, (2010) The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 19: 1049-1066.
11. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, et al. (2005) A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105: 959-967.
12. Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, et al. (2008) Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112: 981-989.
13. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, et al. (2008) Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111: 1060-1066.
14. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, et al. (2006) A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12: 4628-4635.
15. Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, et al. (2008) A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 81: 170-176.
16. Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, et al. (2007) Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109: 2781-2790.
17. Klimek VM, Fircanis S, Maslak P, Guernah I, Baum M, et al. (2008) Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 14: 826-832.
18. Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, et al. (2006) The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106: 112-119.
19. Brazelle W, Kreahling JM, Gemmer J, Ma Y, Cress WD, et al. (2010) Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS ONE 5: e14335.
20. Wang G, He J, Zhao J, Yun W, Xie C, et al. (2012) Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PLoS One 7: e52095.
21. Xie C, Edwards H, Xu X, Zhou H, Buck SA, et al. (2010) Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res 16: 5499-5510.
22. Xu X, Xie C, Edwards H, Zhou H, Buck SA, et al. (2011) Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. PLoS One 6: e17138.
23. Bolden JE, Peart MJ, Johnstone RW, (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
24. Gilbert F, Feder M, Balaban G, Brangman D, Lurie DK, et al. (1984) Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res 44: 5444-5449.
25. Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL, et al. (1981) Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 41: 4678-4686.
26. White PS, Maris JM, Beltinger C, Sulman E, Marshall HN, et al. (1995) A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci U S A 92: 5520-5524.
27. Zaizen Y, Taniguchi S, Noguchi S, Suita S, (1993) The effect of N-myc amplification and expression on invasiveness of neuroblastoma cells. J Pediatr Surg 28: 766-769.
28. Kato Y, Nishimura S, Sakura N, Ueda K, (2003) Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents. Pediatr Int 45: 74-79.
29. Hempel G, Flege S, Wurthwein G, Boos J, (2002) Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Cancer Chemother Pharmacol 49: 133-141.
30. Goodisman J, Souid AK, (2006) Constancy in integrated cisplatin plasma concentrations among pediatric patients. J Clin Pharmacol 46: 443-448.
31. Weiss GJ, Donehower RC, Iyengar T, Ramanathan RK, Lewandowski K, et al. (2013) Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer. Invest New Drugs 31: 136-144.
32. Minucci S, Pelicci PG, (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
33. Prince HM, Bishton MJ, Harrison SJ, (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15: 3958-3969.